Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses

► Confirms delta inulin adjuvant (Advax) enhances influenza vaccine protection. ► Enhanced protection is associated with increased neutralizing antibody and T cell responses. ► Protection can be transferred using immune sera. ► Confirms Advax confers 10- to 100-fold antigen sparing. ► Shows that Advax, like MF59, works as a Th0 type adjuvant.